Title : Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.

Pub. Date : 2006 Aug

PMID : 16688779






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. vandetanib epidermal growth factor receptor Homo sapiens
2 ZD6474 is an orally available, small molecule inhibitor of VEGF receptor-2 (VEGFR-2), EGFR and RET tyrosine kinase activity. vandetanib epidermal growth factor receptor Homo sapiens
3 EXPERIMENTAL DESIGN: The anti-tumor activity in vitro and in vivo of ZD6474 and/or cetuximab was tested in human cancer cell lines with a functional EGFR autocrine pathway. vandetanib epidermal growth factor receptor Homo sapiens